Spiegelberg Hans L, Takabayashi Kenji, Beck Lucinda, Raz Eyal
Department of Pediatrics, University of California, San Diego School of Medicine, La Jolla 92093-0833, USA.
Expert Rev Vaccines. 2002 Aug;1(2):169-77. doi: 10.1586/14760584.1.2.169.
Allergen-specific immunotherapy, although efficacious, is now less frequently used because of potential adverse reactions. Recently, two new types of allergen immunotherapy have been developed that appear to overcome this problem, namely allergen gene vaccination and vaccination with allergen-immunstimulatory DNA conjugates. In animal models of allergy, both have been shown to induce nonallergic T-helper cell type 1 immune responses to allergens and downregulate pre-existing T-helper cell type 2 responses. In initial clinical trials with allergic patients, allergen-immunostimulatory DNA conjugates were well-tolerated, induced immunoglobulin-G but not immunoglobulin-E antibodies and appeared to have great potential as a novel, safe and efficacious type of allergen specific immunotherapy.
变应原特异性免疫疗法虽然有效，但由于存在潜在不良反应，目前使用频率较低。最近，已开发出两种新型变应原免疫疗法，似乎可克服这一问题，即变应原基因疫苗接种和变应原免疫刺激DNA偶联物疫苗接种。在变应性疾病动物模型中，二者均已显示可诱导对变应原的非变应性1型辅助性T细胞免疫应答，并下调已有的2型辅助性T细胞应答。在变应性疾病患者的初步临床试验中，变应原免疫刺激DNA偶联物耐受性良好，可诱导产生免疫球蛋白G而非免疫球蛋白E抗体，并且似乎作为一种新型、安全且有效的变应原特异性免疫疗法具有巨大潜力。
